Delivery of virus-sized iron oxide particles to rodent CNS neurons.

Delivery of viral particles to the brain is limited by the volume of distribution that can be obtained. Additionally, there is currently no way to non-invasively monitor the distribution of virus following delivery to the central nervous system (CNS). To examine the delivery of virus-sized particles across the blood-brain barrier (BBB), dextran coated, superparamagnetic monocrystalline iron oxide particles, with a hydrodynamic diameter of 20 +/- 4 nm, were delivered to rat brain by direct intracerebral inoculation or by osmotic BBB disruption with hypertonic mannitol. Delivery of these particles was documented by magnetic resonance (MR) imaging and, unexpectedly, neuronal uptake was demonstrated by histochemical staining. Electron microscopy (EM) confirmed iron particle delivery across the capillary basement membrane and localization within CNS parenchymal cells following administration with BBB disruption. This is the first histologic and ultrastructural documentation of the delivery of particles the size of virions across the blood-brain barrier. Additionally, these dextran-coated, iron oxide particles may be useful, in and of themselves, as vectors for diagnostic and/or therapeutic interventions directed at the CNS.

[1]  R. Weissleder,et al.  Enhancement of MR angiography with iron oxide: preliminary studies in whole-blood phantom and in animals. , 1994, AJR. American journal of roentgenology.

[2]  F E Bloom,et al.  Human immunodeficiency virus infection of human brain capillary endothelial cells occurs via a CD4/galactosylceramide-independent mechanism. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[3]  E. Neuwelt,et al.  Dexamethasone Decreases the Delivery of Tumor-Specific Monoclonal Antibody to Both Intracerebral and Subcutaneous Tumor Xenografts , 1993 .

[4]  P. Burger,et al.  MR detection of brain iron. , 1993, AJNR. American journal of neuroradiology.

[5]  Pratik Ghosh,et al.  Nuclear Magnetic Resonance (NMR) Imaging of Iron Oxide-Labeled Neural Transplants , 1993, Experimental Neurology.

[6]  C. Olanow,et al.  Infusion of iron into the rat substantia nigra: Nigral pathology and dose‐dependent loss of striatal dopaminergic markers , 1993, Journal of neuroscience research.

[7]  R Weissleder,et al.  Monocrystalline iron oxide nanocompounds (MION): Physicochemical properties , 1993, Magnetic resonance in medicine.

[8]  M. Mattson,et al.  Basic FGF, NGF, and IGFs Protect Hippocampal and Cortical Neurons against Iron-Induced Degeneration , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[9]  N. Rajakumar,et al.  Biotinylated dextran: a versatile anterograde and retrograde neuronal tracer , 1993, Brain Research.

[10]  Ralph Weissleder,et al.  Colloidal magnetic resonance contrast agents : effect of particle surface on biodistribution , 1993 .

[11]  Blake J. Roessler,et al.  A model system for in vivo gene transfer into the central nervous system using an adenoviral vector , 1993, Nature Genetics.

[12]  K. Go,et al.  Magnetite as a potent contrast-enhancing agent in magnetic resonance imaging to visualize blood-brain barrier disruption. , 1993, Acta neurochirurgica. Supplementum.

[13]  R Weissleder,et al.  Drug targeting in magnetic resonance imaging. , 1992, Magnetic resonance quarterly.

[14]  A. Koeppen,et al.  Experimental Superficial Siderosis of the Central Nervous System. I. Morphological Observations , 1991, Journal of neuropathology and experimental neurology.

[15]  R. Braziel,et al.  Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  R. Dix,et al.  Delivery of ultraviolet-inactivated 35S-herpesvirus across an osmotically modified blood-brain barrier. , 1991, Journal of neurosurgery.

[17]  X. Breakefield,et al.  Herpes simplex virus for gene delivery to neurons. , 1991, The New biologist.

[18]  L. Heimer,et al.  In vivo anterograde and retrograde axonal trnasport of the fluoresecent rhodamine-dextran-amine, Fluor-Ruby, within the CNS , 1990, Brain Research.

[19]  R. Martuza,et al.  Transfer and expression of the lacZ gene in rat brain neurons mediated by herpes simplex virus mutants. , 1990, The New biologist.

[20]  R. Weissleder,et al.  Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. , 1990, Radiology.

[21]  N. Greig.  Drug Delivery to the Brain by Blood-Brain Barrier Circumvention and Drug Modification , 1989 .

[22]  R Weissleder,et al.  Superparamagnetic iron oxide: pharmacokinetics and toxicity. , 1989, AJR. American journal of roentgenology.

[23]  E. Neuwelt,et al.  Delivery of melanoma-associated immunoglobulin monoclonal antibody and Fab fragments to normal brain utilizing osmotic blood-brain barrier disruption. , 1988, Cancer research.

[24]  S. Rapoport,et al.  Tight‐Junctional Modification as the Basis of Osmotic Opening of the Blood‐Brain Barrier a , 1986, Annals of the New York Academy of Sciences.

[25]  S. Rapoport,et al.  Effect of osmotic blood-brain barrier disruption on methotrexate pharmacokinetics in the dog. , 1980, Neurosurgery.